Bladder Cancer Weekly

June 15, 2026

Videos

Peer-to-Peer Clinical Conversations

Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein

Michael Oefelein

Michael Oefelein presents phase 1 data on ZH9.

BCG Plus Immune Checkpoint Blockade for High-Grade T1 Bladder Cancer with CIS - Eugene Pietzak

Eugene J. Pietzak

Eugene Pietzak presents an investigator-initiated trial of BCG plus immune checkpoint blockade.

Beyond the Abstracts

Guidance for Avoiding Patient Pain and Discomfort During Transurethral Cystoscopy - Beyond the Abstract

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Final Results and Biomarker Analyses of the SURE-01 Trial

ASCO 2026: Bulumtatug Fuvedotin (BFv; 9MW2821) + Toripalimab in Perioperative Patients with MIBC: Results of Cohort a from a Phase 2 Study

AUA 2026: Patient-reported Recovery Trajectories Following Radical Cystectomy: Findings from the UW Prospective Bounceback Cohort Study

AUA 2026: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer

AUA 2026: A Fully Automated Artificial Intelligence System for Urine Cytology: Results from a Large Multicenter External Validation

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.

Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.

A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.

External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.

Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.

Photocure and Artera to Partner on Digital Pathology AI Test Evaluation for Bladder Cancer

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC